Effects of nipradilol (K-351) on cardiac function in anesthetized open-chest dogs. 1985

M Sakanashi, and K Noguchi, and S Takeo, and H Ito, and Y Miyamoto, and T Kato

Effects of nipradilol (K-351) on cardiac performance and myocardial oxygen consumption were investigated in anesthetized open-chest dogs. Nipradilol 0.1 mg/kg i.v. induced falls in systolic and diastolic aortic blood pressure and left ventricular pressure, and decreases in cardiac output, coronary sinus outflow, left ventricular dP/dt and heart rate. Stroke volume was transiently increased and left ventricular stroke work index was significantly decreased, while left ventricular mechanical efficiency was not significantly changed. Myocardial oxygen consumption was significantly decreased. Total peripheral vascular resistance and coronary vascular resistance were persistently increased. Left ventricular enddiastolic pressure was not significantly changed. These results suggest that nipradilol has a possible antianginal property through a decrease in myocardial oxygen consumption due to a fall in aortic blood pressure and a decrease in heart rate.

UI MeSH Term Description Entries
D009200 Myocardial Contraction Contractile activity of the MYOCARDIUM. Heart Contractility,Inotropism, Cardiac,Cardiac Inotropism,Cardiac Inotropisms,Contractilities, Heart,Contractility, Heart,Contraction, Myocardial,Contractions, Myocardial,Heart Contractilities,Inotropisms, Cardiac,Myocardial Contractions
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D010101 Oxygen Consumption The rate at which oxygen is used by a tissue; microliters of oxygen STPD used per milligram of tissue per hour; the rate at which oxygen enters the blood from alveolar gas, equal in the steady state to the consumption of oxygen by tissue metabolism throughout the body. (Stedman, 25th ed, p346) Consumption, Oxygen,Consumptions, Oxygen,Oxygen Consumptions
D011412 Propanolamines AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives. Aminopropanols
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic
D000758 Anesthesia A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.

Related Publications

M Sakanashi, and K Noguchi, and S Takeo, and H Ito, and Y Miyamoto, and T Kato
September 1984, Archives internationales de pharmacodynamie et de therapie,
M Sakanashi, and K Noguchi, and S Takeo, and H Ito, and Y Miyamoto, and T Kato
November 1981, Japanese heart journal,
M Sakanashi, and K Noguchi, and S Takeo, and H Ito, and Y Miyamoto, and T Kato
January 1987, Journal of cardiovascular pharmacology,
M Sakanashi, and K Noguchi, and S Takeo, and H Ito, and Y Miyamoto, and T Kato
May 1989, Zhongguo yao li xue bao = Acta pharmacologica Sinica,
M Sakanashi, and K Noguchi, and S Takeo, and H Ito, and Y Miyamoto, and T Kato
November 1985, Archives internationales de pharmacodynamie et de therapie,
M Sakanashi, and K Noguchi, and S Takeo, and H Ito, and Y Miyamoto, and T Kato
September 1984, European journal of pharmacology,
M Sakanashi, and K Noguchi, and S Takeo, and H Ito, and Y Miyamoto, and T Kato
January 1985, Journal of cardiovascular pharmacology,
M Sakanashi, and K Noguchi, and S Takeo, and H Ito, and Y Miyamoto, and T Kato
July 1987, Zhongguo yao li xue bao = Acta pharmacologica Sinica,
M Sakanashi, and K Noguchi, and S Takeo, and H Ito, and Y Miyamoto, and T Kato
January 1986, Scandinavian journal of thoracic and cardiovascular surgery,
M Sakanashi, and K Noguchi, and S Takeo, and H Ito, and Y Miyamoto, and T Kato
July 1997, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,
Copied contents to your clipboard!